Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;37(3):301-331.
doi: 10.1007/s40273-018-0746-y.

Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review

Chun-Ru Chien  1   2 , Daniel M Geynisman  3 , Bumyang Kim  4 , Ying Xu  4 , Ya-Chen Tina Shih  5
Affiliations
Review

Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review

Chun-Ru Chien et al. Pharmacoeconomics. 2019 Mar.

Abstract

Background: The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011.

Objective: The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review.

Methods: We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables.

Results: We identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time.

Conclusion: RCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preferred reporting items for systematic reviews and meta-analyses flowchart for literature review.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. ACS. Cancer Facts & Figures 2018. Atlanta, GA: American Cancer Society; 2018.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018. January;68(1):7–30. - PubMed
    1. IARC. Estimated number of incident cases, both sexes, kidney cancer, worldwide in 2012. [cited 2018 April 17]; Available from: https://gco.iarc.fr/today/online-analysis-table?mode=population&mode_pop...
    1. Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin 2017. November;67(6):507–24. - PubMed
    1. Curti BD. Renal cell carcinoma. JAMA 2004. July 7;292(1):97–100. - PubMed

Publication types